BioXXmed Competitors and Similar CompaniesClear all
BioXXmed's competitors and similar companies include Vitrolife, Annexon Biosciences, Themis Bioscience and Fulcrum Therapeutics.
 BioXXmed BioXXmed (formerly known as CytoTools) is a biotechnology company engaged in biomedicine investments. |  Vitrolife Vitrolife is a biotechnology company that develops products to counter fertility issues in humans. |  Annexon Biosciences Annexon Biosciences is a clinical-stage biopharmaceutical company that develops complementary medicines for patients with complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. |  Fulcrum Therapeutics We are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Above all we are champions for our patients. Trust, Respect, Compassion and Integrity define who we are. | ||
Founding Date | Founding Date N/A | Founding Date 1981 | Founding Date 2011 | Founding Date 2009 | Founding Date 2016 |
Type | Type Public | Type Public | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Darmstadt, DE HQ | Locations Västra Frölunda, SE HQ | Locations Brisbane, US HQ | Locations Wien, AT HQ | Locations Cambridge, US HQ |
Employees | Employees 1 | Employees 1,150 | Employees 10041% increase | Employees 373% decrease | Employees 43223% increase |
Valuation ($) | Valuation ($) 151.5 k | Valuation ($) 3.1 b | Valuation ($) 799.8 m | Valuation ($) N/A | Valuation ($) 202.2 m |
Financial | |||||
Revenue (est.) | Revenue (est.) €3k (FY, 2024) | Revenue (est.) kr3.4b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods kr1.3b (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit €34k (FY, 2024) | Gross profit kr2.2b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income (€997k) (FY, 2024) | Net income (kr5b) (FY, 2025) | Net income ($206.7m) (FY, 2025) | Net income N/A | Net income ($74.9m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 179m | Total funding raised $ 81.8m | Total funding raised $ 55m |
For sources of this data, please see the company profile
View Company Profiles
Vitrolife
HQ
Västra Frölunda, SE
Employees
1,150
Vitrolife is a biotechnology company that develops products to counter fertility issues in humans.
View companyAnnexon Biosciences
HQ
Brisbane, US
Employees
100↑ 41% increase
Annexon Biosciences is a clinical-stage biopharmaceutical company that develops complementary medicines for patients with complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye.
View company
Themis Bioscience
HQ
Wien, AT
Themis Bioscience develops vaccines against tropical infections.
View companyFulcrum Therapeutics
HQ
Cambridge, US
Employees
432↑ 23% increase
We are here to develop new medicines to deliver a new future for patients and their families by transforming gene regulation in disease. Above all we are champions for our patients. Trust, Respect, Compassion and Integrity define who we are.
View company